Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02831114 · ClinicalTrials.gov registry record · NA

Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy

A NA study, sponsored by Prisma Health-Upstate.

Completed
Registry status
NA
Development phase
18
Enrollment target

NCT02831114 is a NA study that has completed, run by Prisma Health-Upstate. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02831114, a NA study, has completed, sponsored by Prisma Health-Upstate.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target

Study Summary

Taxane Induced Peripheral Neuropathy (TIPN) is a major dose limiting side effect of taxane chemotherapies and it often reduces the success of the patient treatment. Treating TIPN is difficult and at this time conventional treatment is primarily limited to the global use of antidepressants and anticonvulsants. Acupuncture treatment has been used for symptom improvement in patients with peripheral neuropathy caused by HIV and diabetes mellitus; however, few studies have evaluated acupuncture as a viable treatment for taxane induced peripheral neuropathy. This study will enroll female breast cancer survivors at the Greenville Health System Cancer Institute Center for Integrative Oncology and Survivorship to assess whether acupuncture holds any therapeutic benefit for TIPN and how it influences the mechanisms underlying resolution of TIPN. This would provide critical validation of acupuncture and increase potential for other forms of chemotherapy induced peripheral neuropathy.

Interventions

  • OTHER Acupuncture

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2016-05
Est. Completion 2018-01
Phase NA

Sponsor

Prisma Health-Upstate

67 total trials

What the Registry Record Tells You About NCT02831114

The ClinicalTrials.gov registry entry for NCT02831114 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Acupuncture is the first listed.

NCT02831114 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02831114 about?

NCT02831114 is a clinical study titled "Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy". Taxane Induced Peripheral Neuropathy (TIPN) is a major dose limiting side effect of taxane chemotherapies and it often reduces the success of the patient treatment. Treating TIPN is difficult and at this time conventional treatment is primarily limited to the global use of antidepressants and antico...

What is the current status of trial NCT02831114?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2016-05. Estimated completion is 2018-01.

What interventions are being tested in trial NCT02831114?

The interventions under investigation include: Acupuncture (OTHER).

Who is sponsoring clinical trial NCT02831114?

This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.